Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2015-11-02 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于本次非公开发行相关报告书的补充更正公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding corrections and supplements to previously disclosed reports related to a non-public stock issuance by Kunming Pharmaceutical Group Co., Ltd. It references specific reports such as the "Acquisition Report," "Detailed Equity Change Report," and "Issuance Situation Report," and provides corrected shareholder information and shareholding percentages before and after the issuance. The content focuses on shareholding changes, equity structure, and issuance results, which are typical of announcements related to capital changes. There is no indication that this is a full financial report, audit report, or earnings release. The document is not a simple announcement of a report publication but contains substantive corrections and detailed data. Therefore, the document fits best into the category of Share Issue/Capital Change (SHA).
2015-11-02 Chinese
2015年第四次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, voting procedures, and results of a specific shareholders' meeting (the 2015 fourth extraordinary general meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the legality and validity of the meeting and resolutions passed. It does not contain financial statements or detailed financial performance data, nor is it a report or announcement of financial results. It is not a proxy solicitation or voting results announcement but a legal opinion on the meeting's compliance. Therefore, it fits best under Regulatory Filings (RNS) as a legal compliance document related to corporate governance and shareholder meetings but not a direct governance report or voting result announcement.
2015-11-02 Chinese
华方医药科技有限公司现金认购股份有限公司非公开发行股票收购报告书（修订）
Capital/Financing Update Classification · 95% confidence The document is titled as a "非公开发行股票收购报告书（修订）" which translates to "Non-public Issuance of Shares Acquisition Report (Revised)". It is a detailed acquisition report related to a non-public stock issuance by Kunming Pharmaceutical Group Co., Ltd. The content includes detailed information about the acquirers, their control relationships, business plans, financial data, and legal compliance. The document references relevant Chinese securities laws and regulations governing acquisitions and disclosures. This type of document is a formal acquisition report filed in compliance with securities regulations, detailing the acquisition process and related disclosures. It is not a general annual report, earnings release, or a simple announcement. It is a comprehensive acquisition report, which fits the category of a "Capital/Financing Update" as it relates to a significant financing event (non-public stock issuance and acquisition). Therefore, the appropriate classification is CAP (Capital/Financing Update). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or summary.
2015-11-02 Chinese
2015年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2015 fourth extraordinary general meeting of shareholders of Kunming Pharmaceutical Group Co., Ltd. It includes information about the meeting date, location, attendance, voting results on various proposals including amendments to the company bylaws, election of board members and supervisors, and lawyer's witness statements confirming the legality and validity of the meeting and resolutions. The content focuses on shareholder meeting decisions and voting outcomes rather than financial results or management discussion. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is sufficient and contains substantive voting data and resolutions, not just an announcement of a report or a brief notice. Therefore, the correct classification is DVA with high confidence.
2015-11-02 Chinese
东海证券股份有限公司关于昆药集团股份有限公司本次非公开发行相关报告修订补充的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion issued by Donghai Securities Co., Ltd. regarding corrections and supplements to reports related to a non-public share issuance by Kunming Pharmaceutical Group Co., Ltd. It references specific regulatory rules under the "Acquisition Management Measures" and discusses corrections to a "Detailed Equity Change Report" and an "Acquisition Report." The document is a professional opinion on the accuracy and compliance of these reports, issued by the financial advisor, and does not itself contain financial statements or a full report. It is a regulatory compliance and verification filing related to capital raising activities but is not the capital/financing update itself. Given the nature of the document as a verification opinion on regulatory filings related to a non-public issuance, it best fits under Regulatory Filings (RNS) as it does not present the actual financing update or full report but rather a compliance opinion on related documents.
2015-11-02 Chinese
北京德恒律师事务所关于公司非公开发行股票发行过程和认购对象合规性的法律意见
Capital/Financing Update Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the compliance of a non-public stock issuance process and the subscription objects for Kunming Pharmaceutical Group Co., Ltd. It details the approval and authorization process, issuance scheme, issuance process, verification of subscription funds, and legal compliance. The document references regulatory approvals, legal standards, and compliance checks related to a capital raising event (non-public stock issuance). It is not a financial report, earnings release, or management discussion but a legal opinion specifically tied to a capital/financing activity. The document length is 4472 characters, which is relatively short but contains substantive legal content about the financing event, not just an announcement or a certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2015-10-29 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.